ClinicalTrials.Veeva

Menu
P

ProScience Research Group | Culver City, CA

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

KarXT
Cariprazine
SEP-363856
LB-102
Rapastinel
Lurasidone
Aticaprant
Brexpiprazole
BHV-7000
Lamotrigine

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

14 of 63 total trials

52-week Open Label Safety-Tolerability Study (NOVA3)

Phase 3, open label, multicenter study designed to assess the long term safety and tolerability of LB-102 for the treatment of adult patients with st...

Not yet enrolling
Schizophrenia
Drug: LB-102

X-CEED is a Phase 3, multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of azetukalner in adult part...

Enrolling
Bipolar II Disorder
Bipolar I Disorder
Drug: Placebo
Drug: Azetukalner
Locations recently updated

Bipolar disorder is a severe chronic mood disorder that affects up to 4% of the adult population and 1.8% of the pediatric population in the United S...

Enrolling
Bipolar I Disorder
Depression
Drug: Placebo
Drug: Cariprazine

This is a phase 3, open-label extension study to assess the long-term safety of KarXT for the treatment of mania or mania with mixed features in Bipo...

Enrolling
Bipolar Disorder Type I With Mania
Drug: Valproate
Drug: Lamotrigine

The purpose of this study is to evaluate the efficacy and safety of adjunctive KarXT for the treatment of mania in participants with Bipolar-I Disord...

Enrolling
Bipolar Disorder
Mania
Drug: Placebo
Drug: Xanomeline/Trospium Chloride

This is a Phase 3, randomized, double-blind, placebo-controlled, multicenter, inpatient study in participants with bipolar disorder experiencing an a...

Enrolling
Bipolar Disorder Type I With Mania or Mania With Mixed Features
Drug: KarXT
Other: Placebo

Evaluate the efficacy and safety of Ulotaront (SEP-363856) in acutely psychotic subjects with schizophrenia

Enrolling
Schizophrenia
Drug: SEP-363856
Other: Placebo

This is a Phase 3, multicenter, 52-week, outpatient, open-label extension (OLE) study to evaluate the long-term safety and tolerability of adjunctive...

Enrolling
Schizophrenia
Drug: Xanomeline and Trospium Chloride Capsules

The purpose of this study is to evaluate the efficacy and safety of cariprazine in the treatment of schizophrenia in the adolescent population.

Enrolling
Schizophrenia
Drug: Cariprazine
Drug: Placebo

Efficacy, Safety, and Tolerability of a single administration of COMP360 in participants with treatment-resistant depression (TRD)

Active, not recruiting
Treatment Resistant Depression
Drug: Psilocybin

The purpose of this study is to test the long-term safety of rimegepant in the acute treatment of migraine in children and adolescents (≥ 6 to \< 18...

Enrolling
Acute Treatment of Migraine
Drug: Rimegepant (PF-07899801)

Phase II study for patients with Bipolar 1 Disorder experiencing major depressive episode. Patient eligible for enrollment will be randomized (like f...

Enrolling
Bipolar I Disorder
Other: Placebo
Drug: LB-102

The purpose of this study is to test the safety and efficacy of BHV-3000 versus placebo in the acute treatment of moderate or severe migraine in chil...

Enrolling
Pediatric Migraine
Drug: Rimegepant/BHV3000
Drug: Matching placebo

This is a Phase 3, randomized, double blind, placebo controlled, fixed dose, study designed to evaluate the efficacy, safety, tolerability, and of LB...

Enrolling
Schizophrenia
Other: Placebo
Drug: LB-102 (100 mg tablet)

Trial sponsors

Otsuka logo
AbbVie logo
Allergan logo
Karuna Therapeutics logo
L
Boehringer Ingelheim logo
Bristol-Myers Squibb (BMS) logo
Janssen (J&J Innovative Medicine) logo
Pfizer logo
Sumitomo Pharma logo

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems